Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Dec;205(6):2248-2253.
doi: 10.1111/bjh.19787. Epub 2024 Sep 22.

Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study

Paolo Strati  1 , Rebecca Champion  2 , Morton Coleman  3 , Sonali M Smith  4 , Parameswaran Venugopal  5 , Peter Martin  6 , Andrew Wood  7 , Kara Miller  8 , Beth Christian  9
Affiliations
Clinical Trial

Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study

Paolo Strati et al. Br J Haematol. 2024 Dec.

Abstract

Acalabrutinib is a selective, second-generation Bruton tyrosine kinase inhibitor. In this open-label, parallel-group study, patients with relapsed/refractory (R/R) follicular lymphoma (FL) were randomised to either acalabrutinib monotherapy or acalabrutinib plus rituximab. An additional cohort of patients with treatment-naive (TN) FL received only the acalabrutinib-rituximab combination. Acalabrutinib-rituximab was well tolerated and active in R/R and TN FL; in the TN cohort the overall response rate was 92.3% with most remissions lasting over 4 years. Acalabrutinib monotherapy was also well tolerated and active in R/R FL. These results support further study of acalabrutinib alone and in combination with rituximab in FL.

Keywords: Bruton tyrosine kinase; B‐cell lymphoma; non‐Hodgkin lymphoma.

PubMed Disclaimer

Conflict of interest statement

PS has provided consultancy for Kite‐Gilead, Roche‐Genentech, Hutchinson MediPharma, ADC Therapeutics, Incyte Morphosis, Ipsen; has received research funding from Sobi Pharmaceuticals, AstraZeneca/Acerta, ALX Oncology, ADC Therapeutics; and has received salary support from the Leukemia Lymphoma Society Scholar in Clinical Research Career Development Program, Sabin Fellowship Award and Gilead Scholar in Clinical Research Award. RC has participated in a speakers' bureau for AbbVie. MC has nothing relevant to disclose. SMS has provided consultancy for Genmab. PV has nothing relevant to disclose. PM has provided consultancy for AbbVie, AstraZeneca, BeiGene, Daiichi Sankyo, Janssen, Merck and PeproMene. AW is an employee of AstraZeneca. KM is an employee of AstraZeneca. BC has participated in advisory boards for Ipsen; has received research funding (paid to institution) from AstraZeneca/Acerta Pharma, Genentech, Bristol Myers Squibb, and Millennium Pharmaceuticals.

References

    1. Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33:2516–2522. - PMC - PubMed
    1. Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high‐risk subgroups. Blood Cancer J. 2020;10:74. - PMC - PubMed
    1. Ghione P, Palomba ML, Ghesquieres H, Bobillo S, Patel AR, Nahas M, et al. Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR‐5 study. Haematologica. 2023;108:822–832. - PMC - PubMed
    1. Gouni S, Marques‐Piubelli ML, Strati P. Follicular lymphoma and macrophages: impact of approved and novel therapies. Blood Adv. 2021;5:4303–4312. - PMC - PubMed
    1. Lam KP, Kühn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell. 1997;90:1073–1083. - PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources